Public RNA sequencing data indicate that CREB3L2 is upregulated in a variety of tumors, including HCC (Fig. 1A and Supplementary Fig. S1A), while HCC patients with high CREB3L2 expression demonstrated a lower overall survival (OS) rate compared to those with lower expression levels (Fig. 1C). This evidence concerns the gene CREB3L2 and hepatocellular carcinoma.